A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis

Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the trea...

Full description

Saved in:
Bibliographic Details
Published in:Gut microbes 2020-11, Vol.12 (1), p.1814119-1814119
Main Authors: Shelby, Rita D., Janzow, Grace E., Mashburn-Warren, Lauren, Galley, Jeffrey, Tengberg, Natalie, Navarro, Jason, Conces, Miriam, Bailey, Michael T., Goodman, Steven D., Besner, Gail E.
Format: Article
Language:English
Subjects:
biofilm
C. difficile
lactobacillus reuteri
probiotics
prophylactic treatment
Research Paper
therapeutic treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by C. difficile oral gavage. For treatment therapy, mice received antibiotics and C. difficile first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to C. difficile demonstrated CSS ≥ 6, which is consistent with C. difficile infection (p
ISSN:1949-0976
1949-0984
DOI:10.1080/19490976.2020.1814119